Whalesbook
India's medical glove manufacturers are facing a serious threat from an influx of cheap, substandard imported gloves. This problem is pushing down prices, straining local producers already dealing with post-pandemic overcapacity, and raising concerns for patient safety.
Local makers are operating below capacity, losing money due to unfair competition. Imports often lack necessary certifications like BIS standards and fail basic quality benchmarks (AQL), crucial for ensuring gloves don't have holes or leaks. While medical gloves typically need an AQL of 1.5 or less, these imports are much worse. Products are sold for as little as one rupee each, forcing down prices for compliant local makers. Beyond economic hits, these non-compliant gloves can spread infections, cause allergies, or fail under pressure, posing a serious hidden threat to patient safety. The Indian medical glove market was valued at about $0.62 billion in 2024 and is projected to reach $0.87 billion by 2030, a growth trajectory now at risk.
The main issue is the long delay in enacting a mandatory Quality Control Order (QCO) for medical and surgical gloves. A draft QCO was circulated in 2024, proposing required BIS certification and the ISI mark, aligning with international rules like ISO and ASTM. However, the QCO, sent to the World Trade Organization (WTO) in February 2025, is still awaiting formal approval and enforcement. This regulatory lag creates a loophole, allowing stockpiling and repackaging of gloves not meant for medical use, often coming through production hubs like Malaysia and Thailand. While Western countries ban chlorinated gloves, India still sees them. Local makers follow strict rules like IS 13422 for surgical gloves, needing AQLs as low as 0.65. The lack of enforcement contradicts the goals of 'Make in India' and India's self-reliance program, which aim to boost local medical device manufacturing, a sector worth about $12 billion in FY 2023-24.
This failure to enact the QCO shows worrying regulatory inaction. Dishonest importers exploit this gap, flooding the market with poor quality items often repackaged locally after large bulk imports. This ruins any chance of fair competition and unsettles local makers, who struggle with importing raw materials and are smaller than global players like Top Glove. The situation also increases the risk of widespread hospital infections (HAIs). Importing unapproved gloves, even though rules ban chlorinated ones, shows weak checks by customs and regulators. This threatens India's goals for making essential medical supplies locally and mirrors wider problems in the medical device sector. The QCO delay, meant to cover about ₹600-700 crore of annual glove imports, lets unapproved products, many not meeting BIS standards, enter freely.
Industry groups are strongly urging quick approval and enforcement of the QCO. Getting this done quickly is seen as vital to stop bad imports, ensure fair play, and boost good local production. Analysts expect the Indian medical glove market to grow, possibly reaching $0.87 billion to $1.4 billion by 2030, if rules improve and competition is fairer. The sector's success depends on strong policy action, which could make India a global glove production center and strengthen its healthcare independence.